Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Nuscale Power Corporation — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Nuscale Power Corporation trades at $5.75 (market cap $2.75B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 3.2× Nuscale Power Corporation's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Nuscale Power Corporation for 30 Days on average.
| KYMR | SMR | |
|---|---|---|
Market Cap | $8.87B | $2.75B |
Volume | 779,107 | 40,865,576 |
Sector | Health | Industrials |
52-Week High | $127.31 | $53.43 |
52-Week Low | $55.80 | $5.83 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $8.26B | $1.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NuScale Power (SMR) trades at $6.495, down 3.06% on the day, reflecting ongoing operational losses and negative investor sentiment. The stock exhibits a bearish technical signal, with moving averages indicating strong selling pressure, though oversold oscillators suggest potential for a near-term bounce. Fundamentally, the company reported a net loss of $355.79M on revenue of $31.48M in 2025, with a deeply negative net income margin of -3,888.7% in 2026, highlighting severe profitability challenges despite operating in the high-potential nuclear energy sector.
The outlook remains highly speculative. Analyst consensus is a 'Buy' with a $11.25 price target, implying significant upside, but this is contingent on successful commercialization of its small modular reactor technology. Primary risks include persistent cash burn, intense competition, and the high capital and regulatory hurdles inherent in nuclear power development. The stock represents a high-risk, high-reward opportunity for investors betting on a future nuclear renaissance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
